TECH Bio-Techne Corporation

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]

Bio-Techne has outperformed the Nasdaq over the past year, but analysts are cautious about the stock’s prospects.

Bio-Techne has had an impressive run over the past six months as its shares have beaten the S&P 500 by 21.5%. The stock now trades at $72.56, marking a 39.5% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Bio-Techne (TECH) has drawn fresh attention after recent trading left the share price at $72.27, with performance over the past month roughly flat and the past 3 months showing a strong double digit gain. Recent trading tells a mixed story for Bio-Techne. The share price return of 29% over the past 90 days sits alongside a 1-year total shareholder return of 41%, while the 5-year total shareholder return shows a decline of 44%. This hints that momentum has only recently improved following a...

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bio-Techne (NASDAQ:TECH) and its peers.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Bio-Techne has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 per share was in line with analysts’ consensus estimates.

Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium rather than as an obvious bargain. Over the last 12 months, Bio-Techne has returned 44.2%, which puts a clear spotlight on whether recent gains already reflect much of the good news in the price. Expectations around Bio-Techne's ability to grow revenue and sustain healthy cash flows...

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.

TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.

Bio-Techne is scheduled to post its fourth-quarter results soon, and analysts project a single-digit earnings decline.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry.